Cornea transplant rejection happens when your immune system identifies the donor tissue as foreign and attacks it, threatening the clarity of the graft and your vision. It can occur weeks, months, or even years after surgery, though the risk is highest in the first one to two years. The good news is that the cornea is one of the most successfully transplanted tissues in the body, partly because the eye has built-in defenses against immune reactions. When rejection does happen, catching it early and treating it aggressively with corticosteroids reverses the process in the majority of cases.
Why the Cornea Gets a Head Start Against Rejection
The eye is one of the few places in the body with what researchers call “immune privilege,” meaning the immune system is kept on a shorter leash there than in most other tissues. Three main mechanisms create this protection. First, the cornea itself lacks blood vessels and has limited lymphatic drainage under normal conditions, which physically limits the traffic of immune cells to and from the graft. Second, the eye generates a form of immune tolerance through processes involving the fluid in the front chamber, which promotes regulatory immune cells that suppress inflammatory reactions. Third, the interior of the eye maintains a chemical microenvironment loaded with molecules that actively tamp down immune responses.1PubMed. Immune privilege in corneal transplantation
This triple layer of protection is the reason cornea transplants succeed without the aggressive full-body immunosuppression that kidney or liver recipients need. But that privilege can break down. Injuries, infections, or previous surgeries can trigger blood vessels and lymphatic vessels to grow into the cornea, breaching its natural barriers and opening the door for immune cells to reach the graft.2PubMed Central. The role of lymphatic vessels in corneal fluid homeostasis and wound healing When that vascular invasion happens, rejection rates climb sharply.
Recognizing the Signs of Rejection
Rejection rarely announces itself with a single unmistakable symptom. Instead, it tends to build gradually, and the earliest changes can be subtle enough to miss if you are not watching for them. Doctors have identified three distinct patterns, each targeting a different layer of the cornea: endothelial rejection (affecting the innermost cell layer), epithelial rejection (affecting the outermost surface), and subepithelial infiltrates, which are small inflammatory deposits just beneath the surface.3JAMA Ophthalmology. Clinical Types of Corneal Transplant Rejection: Their Manifestations, Frequency, Preoperative Correlates, and Treatment Endothelial rejection is the most serious of the three because the innermost cells do not regenerate well on their own. If those cells are destroyed, the cornea swells irreversibly and the graft fails.
The classic warning signs that patients are taught to watch for are sometimes summarized with the mnemonic RSVP:
- Redness: new or worsening redness around the cornea, especially if it was not there before
- Sensitivity: increased sensitivity to light
- Vision loss: blurred or hazy vision that develops over days rather than suddenly
- Pain: aching or discomfort in or around the eye
Any one of these symptoms in a transplanted eye warrants an urgent visit to your ophthalmologist. Under the slit lamp, the doctor looks for specific findings like a line of inflammatory cells on the back surface of the graft (called a Khodadoust line in endothelial rejection), corneal swelling, or scattered hazy spots. The timing matters too: rejection episodes often cluster in the months following any change in steroid treatment, an eye infection, or even a systemic illness that revs up the immune system.
Telling Rejection Apart From Infection
One of the trickier aspects of post-transplant care is distinguishing a rejection episode from an infection in the graft. Both can produce redness, pain, and reduced vision. Infections after keratoplasty can present as central or peripheral corneal ulcers, often accompanied by stromal infiltration and inflammation in the front chamber of the eye.4Survey of Ophthalmology. Infectious Keratitis Following Keratoplasty Peripheral infections are frequently linked to sutures, while central ulcers tend to develop when the surface epithelium is compromised. The key difference is that infections usually progress faster, may have a white or yellow infiltrate visible on the cornea, and often respond to antimicrobial treatment rather than steroids. Misdiagnosing an infection as rejection and flooding the eye with steroids can make things dramatically worse, so cultures and careful clinical assessment are critical when the picture is ambiguous.
What Raises Your Risk
Not every transplant faces the same odds. Several factors push the risk of rejection higher, and understanding them helps explain why some patients need closer monitoring or more aggressive prevention. The biggest single risk factor is the presence of blood vessels growing into the recipient’s cornea, particularly when the vascularization extends across two or more quadrants of the cornea. Other major risk factors include corneal scarring from an infection, post-traumatic corneal opacity, a graft diameter larger than about 8 mm, and having a transplant done for therapeutic rather than optical reasons.5Transplantation Proceedings. Epidemiology and Risk Factors for Corneal Graft Rejection
More recently, machine-learning analyses have identified additional factors that contribute to rejection risk: patient age, donor age, the density of endothelial cells in the donor tissue, how long corticosteroids are used after surgery, the timing of suture removal, and complications related to sutures themselves.6PubMed Central. Machine learning methods to identify risk factors for corneal graft rejection in keratoconus Having a transplant in the fellow eye (meaning a graft in the other eye as well) also increases risk, presumably because the immune system has already been sensitized to donor corneal tissue. These factors interact in complex ways, which is why the same surgery can have very different rejection profiles in two different patients.
How Surgical Technique Affects Rejection Rates
The type of transplant procedure matters more than many patients realize. Traditional full-thickness transplantation (penetrating keratoplasty, or PK) replaces all layers of the cornea and carries a moderate rejection risk. Newer partial-thickness techniques target only the diseased layer. For diseases affecting the innermost endothelial layer, two options now dominate: DSAEK, which transplants a thicker partial layer, and DMEK, which transplants only the thin endothelial sheet.
A ten-year follow-up study comparing these three procedures found that the cumulative probability of suspected rejection was highest after DSAEK (about 19%), followed by PK (about 13%), while DMEK had the lowest rate (about 10%). The difference between DMEK and PK was statistically meaningful, while DSAEK and PK were not significantly different from each other.7PubMed Central. Ten-year outcomes after DMEK, DSAEK, and PK: insights on graft survival, endothelial cell density loss, rejection and visual acuity DMEK’s advantage likely comes from the smaller amount of foreign tissue being introduced and a tighter fit against the recipient’s own cornea. If your surgeon recommends DMEK and the disease allows it, the lower rejection rate is one real advantage to consider.
First-Line Treatment When Rejection Strikes
Corticosteroid eye drops are the backbone of both prevention and treatment of rejection. After transplant surgery, you will typically use steroid drops on a tapering schedule for at least twelve months, sometimes longer.8PubMed Central. Objective measurement of adherence to topical steroid medication after penetrating keratoplasty using an electronic monitoring aid If a rejection episode is diagnosed, the standard approach is to increase drop frequency dramatically, sometimes to every hour during waking hours. In more severe cases, doctors add an intravenous pulse of high-dose methylprednisolone.
A five-year case series using combined intravenous methylprednisolone with oral cyclosporine successfully reversed rejection in about 94% of treated eyes.9Eye. Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience That is an encouraging figure, but it comes with a caveat: the key variable is how quickly treatment starts. Rejection caught within days responds far better than rejection that has been smoldering for weeks. This is the main reason doctors spend so much time teaching patients the warning signs.
Long-term heavy steroid use comes with its own problems, particularly elevated eye pressure that can damage the optic nerve. Researchers have been developing sustained-release formulations to reduce the burden. One approach uses nanoparticle-loaded dexamethasone injected under the conjunctiva, delivering steady drug levels for up to six months from a single dose and reversing early rejection signs in animal models without affecting eye pressure.10PubMed Central. Six-month effective treatment of corneal graft rejection If that technology translates to humans, it could eliminate the daily drop burden that so many patients struggle with.
When Stronger Immunosuppression Is Needed
For high-risk patients, topical steroids alone are not enough. Systemic immunosuppressive drugs enter the picture, and tacrolimus has become a preferred choice. A study of 43 high-risk patients treated with systemic tacrolimus for 18 to 24 months maintained clear grafts in about 65% of cases over an average follow-up of nearly three years.11PubMed Central. Tacrolimus immunosuppression in high-risk corneal grafts Eight patients still experienced rejection while on the drug, and five of those grafts failed, so tacrolimus is not a guarantee. But compared to historical outcomes for similar high-risk cases, it represents a meaningful improvement.
Topical tacrolimus drops are also being explored as an alternative to systemic dosing. A randomized trial comparing topical tacrolimus to standard treatment in high-risk transplants found no rejection episodes in the tacrolimus group, though the study was small.12PubMed Central. Topical tacrolimus for high-risk corneal transplantation: a randomized, clinical trial Topical cyclosporine, a related drug, has a more mixed track record. A Cochrane review found inconsistent results for topical cyclosporine in normal-risk transplants: one trial showed fewer rejection episodes, while another actually showed more rejection episodes in the cyclosporine group.13Cochrane Database of Systematic Reviews. Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty The evidence here is genuinely unsettled, and your ophthalmologist’s choice among these agents will depend on your specific risk profile.
Does HLA Matching Help
Tissue matching is standard practice for organ transplants, but it has historically been skipped for most cornea transplants because of the cornea’s immune privilege. The question of whether matching human leukocyte antigens (HLA) between donor and recipient would improve outcomes has been debated for decades. The evidence is clearest for high-risk recipients. In a landmark study, patients who received a well-matched graft (sharing two or more HLA-A and HLA-B antigens) had a rejection rate of about 21%, compared to roughly 49% in poorly matched recipients. At two years, rejection-free graft survival was about 80% in the well-matched group versus under 40% in the poorly matched group.14PubMed. Reduced graft rejection with good HLA-A and B matching in high-risk corneal transplantation
More recent analysis supports the idea that even normal-risk transplants benefit from HLA matching when modern DNA-based typing methods are used, particularly for HLA Class I.15Progress in Retinal and Eye Research. Matching for Human Leukocyte Antigens (HLA) in corneal transplantation – To do or not to do Despite this evidence, routine matching is still not performed in most countries because of logistical challenges: corneas have a limited shelf life, and matching delays access to tissue. The practice is more common in high-risk situations where the expected benefit justifies the added complexity.
Pretreating Vascularized Corneas Before Surgery
For patients with blood vessels and lymphatic vessels already growing into their cornea, one of the most promising strategies is to treat those vessels before the transplant, rather than simply operating and hoping for the best. Fine needle diathermy, a technique that uses heat from a tiny needle to cauterize individual vessels, can regress both blood and lymphatic vessels in the cornea. In an animal study, combining this treatment with anti-inflammatory eye drops before transplantation improved graft survival at eight weeks to about 61%, compared to just 8% in untreated controls.16PubMed Central. Fine Needle-Diathermy Regresses Pathological Corneal (Lymph)Angiogenesis and Promotes High-Risk Corneal Transplant Survival
There is a catch, however. The diathermy itself triggers a rebound: blood vessels start regrowing within a week. Adding a VEGF-blocking agent after the procedure prevents this rebound, achieving sustained regression of blood vessel area by over 50% and lymphatic vessel area by about 65% compared to diathermy alone.17Scientific Reports. Supplemental Anti Vegf A-Therapy Prevents Rebound Neovascularisation After Fine Needle Diathermy Treatment to Regress Pathological Corneal (LYMPH)Angiogenesis This combined approach is still being refined for clinical use, but it represents a shift in thinking: rather than treating rejection after it happens, it aims to restore the cornea’s natural immune privilege before the graft is placed.
The Medication Adherence Problem
The most effective anti-rejection drug in the world does nothing if it stays in the bottle. Adherence to post-transplant steroid drops is one of the most underappreciated risks for graft failure, and the numbers are sobering. Studies of corneal transplant recipients have reported non-adherence rates ranging from about 29% to 66%.18PubMed Central. Medication Adherence Among Patients with Corneal Diseases That means at least a third of patients are not using their drops as prescribed at some point during the critical post-operative period. The pattern mirrors what happens with glaucoma medications: when a condition is not causing obvious daily symptoms, people tend to deprioritize their drops, especially when treatment extends over many months.
If you have had a cornea transplant, treating your drops as non-negotiable during the first year is the single most impactful thing you can do to protect your graft. Setting phone reminders, keeping drops in the same visible spot, and understanding that you can feel perfectly fine while rejection is beginning underneath can all help close the adherence gap.
Rejection in Children
Pediatric cornea transplants are a different ballgame. Children have more vigorous immune systems, are more likely to rub or traumatize the eye, and cannot reliably describe symptoms like blurred vision or sensitivity to light. They also face an additional risk that adults do not: amblyopia, or “lazy eye,” which can develop if the transplant causes prolonged visual disturbance during the critical window of visual development.19PubMed Central. Pediatric corneal transplantation: techniques, challenges, and outcomes
Rejection outcomes in children tend to be worse. In one pediatric series, about 12% of transplants experienced a rejection episode, but of those, 75% did not respond to treatment and ended in graft failure. The average time to rejection was around ten months after surgery.20PubMed Central. Graft rejection in pediatric penetrating keratoplasty: Clinical features and outcomes The high failure rate underscores how aggressive rejection can be in young patients and why post-operative management requires particularly close follow-up, often with examinations under anesthesia in very young children.
When a Graft Fails and Repeat Transplant Is Needed
A failed graft is not the end of the road, but repeat transplants carry higher risks than the first. The immune system has now been exposed to donor tissue, and the cornea may have developed the vascularization that makes rejection more likely. In one large series of repeat penetrating keratoplasties, graft survival was 98% at one year, 83% at two years, but dropped to 49% at five years. Visual outcomes were also more modest: only about 30% of eyes achieved vision better than 20/200, and fewer than 5% reached 20/40.21PubMed Central. Repeat penetrating keratoplasty: indications, graft survival, and visual outcome Results varied widely by the underlying disease, with keratoconus patients faring best and Fuchs’ dystrophy patients faring worst.
A Dutch registry study of repeat transplants found overall five-year regraft survival of about 60%, with partial-thickness techniques (re-EK) showing better raw survival numbers than repeat full-thickness grafts (about 81% versus 55%), though after adjusting for other variables the difference between techniques was not statistically significant.22American Journal of Ophthalmology. Long-term Outcomes of Repeated Corneal Transplantations: A Prospective Dutch Registry Study The takeaway for patients facing a regraft is that success is possible but depends heavily on the reason the first graft failed and the condition of the eye going into the second surgery.
Alternatives When Donor Grafts Keep Failing
For patients who have been through multiple failed transplants, a prosthetic cornea (keratoprosthesis) offers an alternative to relying on donor tissue entirely. The most widely used device in this category has shown less frequent graft failure, greater visual improvement, and a greater likelihood of maintaining that improvement over time compared to another round of donor tissue transplantation in patients with a history of previous graft failures.23PubMed Central. Donor Corneal Transplantation vs Boston Type 1 Keratoprosthesis in Patients with Previous Graft Failures Keratoprosthesis surgery is not without its own set of complications, including the need for lifelong antibiotic drops and monitoring for issues like retroprosthetic membrane formation and glaucoma. But for patients who have exhausted conventional options, it can be transformative.
Another frontier is cell-based therapy. Researchers have shown that cultured human corneal endothelial cells, when injected into the front chamber of the eye along with a compound called a ROCK inhibitor, can repopulate a damaged endothelial layer and restore corneal clarity.24PubMed. Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy Preclinical work in primates demonstrated that this approach enables cell engraftment and endothelial regeneration, sidestepping the need for donor tissue altogether.25Scientific Reports. Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction If cell injection therapy matures, it could eventually reduce the global dependency on donated corneas and offer a less invasive option for conditions like Fuchs’ dystrophy and bullous keratopathy, where the endothelial layer is the primary problem.
How Rejection Affects Quality of Life
Even when a rejection episode is successfully treated, it can leave a mark on visual function and daily life. Patients who experienced at least one rejection episode had measurably worse visual acuity compared to those with no rejection history, even after treatment. Self-reported quality-of-life scores trended lower in the rejection group as well, though the difference in questionnaire scores was not as statistically clear-cut as the visual acuity difference.26PubMed Central. Patient-Reported Outcomes Following Corneal Transplantation Each rejection episode, even if reversed, may cause some degree of endothelial cell loss that cannot be recovered, gradually thinning the reserve of cells that keep the cornea clear.
On the brighter side, the overall satisfaction with cornea transplantation remains high. In a quality-of-life study, visual function scores improved in about 79% of patients by six months after surgery, 80% were moderately to very satisfied with their vision, and 97% said they would have the surgery again.27American Journal of Ophthalmology. Assessment of visual function after corneal transplantation: the quality of life and psychometric assessment after corneal transplantation (Q-PACT) study Rejection is a real and sometimes serious complication, but the overwhelming majority of transplant recipients come out of the process glad they went through it.
Vaccine-Related Rejection Episodes
A question that surfaced during the COVID-19 pandemic was whether vaccination could trigger graft rejection. A systematic review identified 36 eyes that experienced acute corneal graft rejection following SARS-CoV-2 vaccination. About half of those cases occurred after the first vaccine dose, and the median time between vaccination and rejection symptoms was roughly nine days. Most rejection episodes that responded to treatment resolved within about three weeks, but roughly 14% of grafts ultimately failed.28Acta Ophthalmologica. Acute corneal allograft rejection following SARS-CoV-2 vaccination-A systematic review Eyes with a prior history of immune reactions or multiple previous grafts appeared overrepresented in these cases. The absolute numbers remain tiny relative to the millions of vaccinated transplant recipients worldwide, and no one is recommending against vaccination. But if you have a corneal graft, it is reasonable to watch for rejection symptoms in the two weeks following any vaccination and contact your eye doctor promptly if something feels off.